Indicated as monotherapy for Grown ups with HR-beneficial, HER2-adverse Innovative or metastatic breast cancer with sickness progression following endocrine therapy and prior chemotherapy in metastatic placing 200 mg PO BID Some Negative effects may well arise that sometimes do not want clinical